Abstract
Faricimab, a novel drug in the field of ophthalmology, has garnered attention because of its promising applications in the treatment of various ocular conditions. This drug, with its dual targeting of angiopoietin-2 and vascular endothelial growth factor (VEGF), is a versatile intervention for the management of neovascular and inflammatory ocular disorders. Developed through meticulous research and clinical trials, faricimab holds promise as a multifaceted solution to longstanding challenges in ophthalmology. This review provides a comprehensive analysis of the current knowledge and clinical use of faricimab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
